Table 2.
Changes in rheumatoid arthritis (RA)-related parameters at 3 and 6 months after tocilizumab.
| Parameter | Baseline | 3 Months (V1) | 6 Months (V2) | p-Value |
|---|---|---|---|---|
| DAS28-CRP (mean ± SD) | 5.36 ± 1.67 | 3.39 ± 0.57 | 2.41 ± 0.19 | * <0.05; ** <0.05 |
| SDAI (mean ± SD) | 34.2 ± 16.3 | 18.1 ± 8.2 | 11.1 ± 4.3 | * <0.05; ** <0.05 |
| Number of tender joints (mean ± SD) | 12.31 ± 4.29 | 4.56 ± 1.31 | 3.55 ± 1.13 | * <0.05; ** NS |
| Number of swollen joints (mean ± SD) | 10.01 ± 3.37 | 2.85 ± 4.22 | 1.50 ± 2.09 | * <0.05; ** NS |
| Pain VAS mm (mean ± SD) | 82.7 ± 21.5 | 28.8 ± 23.2 | 16.3 ± 11.8 | * <0.05; ** <0.05 |
| Serum anti-CCP titer (U/mL) (mean ± SD) | 239.7 ± 124.3 | 192.6 ± 112.4 | 123.6 ± 101.6 | * <0.05; ** NS |
| Serum RF levels (IU/mL) (mean ± SD) | 192.7 ± 85.3 | 164.8 ± 92.5 | 151.7 ± 89.3 | * NS; ** NS |
| Serum CRP levels (mg/dL) (mean ± SD) | 15.3 ± 6.9 | 4.12 ± 0.92 | 3.92 ± 0.34 | * <0.05; ** NS |
SD; standard deviation; DAS28-CRP, Disease activity score on 28 joints based on C-reactive protein; SDAI, Simplified Disease Activity Index; VAS, 0–10 cm visual analogue scale; CCP, cyclic citrullinated peptide; RF, rheumatoid factor; V, visits; * V1 compared to baseline; ** V2 compared to V1; NS, non-significant (0.05).